Mar 12, 2021
An early clinical trial in individuals with the deadly brain cancer glioblastoma showed an experimental spherical nucleic acid drug developed by Northwestern University scientists was able to penetrate the blood-brain barrier and trigger the death of tumor cells. Lead investigator Priya Kumthekar, MD, explains the results of the study.